Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orexo ABORXOY 37 Equity-to-Asset is 0.53 as of Jun. 2026, which is 83% above its 10-year median of 0.29. GuruFocus rates ORXOY with a GF Score™ of 37/100 and a GF Value™ of $0.32 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Orexo AB ranks worse than 61.27% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Orexo AB's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $28.51 Mil. Orexo AB's Total Assets for the quarter that ended in Jun. 2026 was $54.08 Mil.
Therefore, Orexo AB's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.53.
The historical rank and industry rank for Orexo AB's Equity-to-Asset or its related term are showing as below:
ORXOY'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.43 Med: 0.29 Max: 0.6
Current: 0.53
During the past 13 years, the highest Equity to Asset Ratio of Orexo AB was 0.60. The lowest was -0.43. And the median was 0.29.
ORXOY's Equity-to-Asset is ranked worse than 61.27% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs ORXOY: 0.53
Orexo AB (OTCPK:ORXOY) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Orexo AB Equity-to-Asset Related Terms
Orexo AB Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Orexo AB's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orexo AB Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orexo AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Orexo AB's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Orexo AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orexo AB (ORXOY) has a Equity-to-Asset of 0.53 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Orexo AB and its competitors. This is 83% above median its historical median of 0.29. According to the industry distribution chart, Orexo AB ranks #617 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 61.3%.
Is Orexo AB's Equity-to-Asset too high?
Orexo AB's current Equity-to-Asset of 0.53 is 83% above median its 10-year median of 0.29. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Orexo AB's value of 0.53 is 13.1% below this industry median. Based on the distribution chart, Orexo AB ranks #617 out of 1007 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Orexo AB has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orexo AB's Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Orexo AB ranks #617 out of 1007 companies for Equity-to-Asset. This places Orexo AB in the lower half of its industry. The industry median Equity-to-Asset is 0.61. Orexo AB's value of 0.53 is 13.1% below this benchmark. While the company's 10-year median is 0.29 vs. the industry median of 0.61, Orexo AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orexo AB's current Equity-to-Asset of 0.53 is 13.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Orexo AB and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orexo AB's current Equity-to-Asset is 0.53, which is 83% above median its own 10-year median of 0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orexo AB stock overvalued right now?
Based on GuruFocus' analysis, Orexo AB (ORXOY) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.32, compared to a current price of $1.77 — trading 453.1% above its estimated fair value. The current Equity-to-Asset is 0.53, which is 83% above median its 10-year median of 0.29 and 13.1% below the Drug Manufacturers industry median of 0.61. Orexo AB's overall GF Score™ is 37/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Orexo AB (ORXOY), the current Equity-to-Asset is 0.53 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orexo AB (ORXOY) Overvalued in 2026?
Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued.
The current stock price of $1.77 is trading 453.1% above its estimated GF Value™ of $0.32.
GuruFocus considers Orexo AB to be Significantly Overvalued.
Key valuation signals for ORXOY:
Equity-to-Asset: 0.53 (83% above median its 10-year median of 0.29)
GF Value™: $0.32 vs. price of $1.77 (453.1% above fair value)
Industry Position: 13.1% below the Drug Manufacturers median (#617 of 1007)
No single metric tells the full story. See the ORXOY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
37GF Score
Get the complete analysis for ORXOY
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORXOY has been successfully added to your 
